Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
financial results, highlighting a period of significant clinical and regulatory progress for its neuroinflammatory disease platform. The company ended the year with a strong balance sheet featuring $238.3 million in cash and short-term investments, a figure supported by an $86.3 million public offering in late 2025. This capital is expected to provide a financial runway into H2 2027, supporting the advancement of two late-stage registrational programs and an emerging oral inhibitor. The company's lead candidate, vonaprument, is currently being evaluated in the ARCHER II Phase 3 trial for geographic atrophy/GA, with topline data anticipated in Q4 2026. Unlike existing treatments that target downstream proteins, vonaprument utilizes an upstream C1q blockade designed to protect photoreceptor neurons and preserve vision. Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential The program has notably received PRIME designation from the European Medicines Agency, establis
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon Biosciences (ANNX) Buy Rating Retained [Yahoo! Finance]Yahoo! Finance
- Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing [Yahoo! Finance]Yahoo! Finance
- Annexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswire
ANNX
Earnings
- 3/30/26 - Beat
ANNX
Sec Filings
- 4/27/26 - Form ARS
- 4/27/26 - Form DEFA14A
- 4/27/26 - Form DEF
- ANNX's page on the SEC website